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BACKGROUND. In addition to Breslow depth, the authors previously described how
increasing mitotic rate and decreasing age predicted sentinel lymph node (SLN) me-
tastases in patients with melanoma. The objectives of the current study were to verify
those previous results and to create a prediction model for the better selection of
which patients with melanoma should undergo SLN biopsy.
METHODS. The authors reviewed 1130 consecutive patients with melanoma in a pro-
spective database who underwent successful SLN biopsy. After eliminating patients
aged <16 years and patients who had melanomas that measured <1 mm, 910
remaining patients were reviewed for clinical and pathologic features and positive
SLN status. Univariate association of patient and tumor characteristics with positive
SLN status was explored by using standard logistic regression techniques, and the
best multivariate model that predicted lymph node metastases was constructed by
using a backward stepwise-elimination technique.
RESULTS. The characteristics that were associated significantly with lymph nodemetas-
tasis were angiolymphatic invasion, the absence of regression, increasing mitotic rate,
satellitosis, ulceration, increasing Breslow depth, decreasing age, and location (trunk or
lower extremity compared with upper extremity or head/neck). Previously reported
interactions between mitotic rate and age and between Breslow depth and age were
confirmed. The best multivariate model included patient age (linear), angiolymphatic
invasion, the number of mitoses (linear), the interaction between patient age and the
number of mitoses, Breslow depth (linear), the interaction between patient age and Bre-
slow depth, and primary tumor location.
CONCLUSIONS. Younger age, increasing mitotic rate (especially in younger patients),
increasing Breslow depth (especially in older patients), angiolymphatic invasion, and
trunk or lower extremity location of the primary tumor were associated with a greater
likelihood of positive SLN status. The current results support the use of factors beyond
Breslow depth to determine the risk of positive SLN status in patients with cutaneous
melanoma. Cancer 2007:109:100–8. 2006 American Cancer Society.
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S entinel lymph node (SLN) biopsy has become an important andwidely employed technique for detecting subclinical metastases
to lymph nodes in patients with cutaneous melanoma. Identifying
lymph node micrometastases facilitates more accurate staging and
identifies patients who may benefit from an early, complete lymph
node dissection and adjuvant therapy or clinical trial consideration.1–4
For this reason, a number of investigators have sought to identify fac-
tors that may predict patients at higher or lower risk of having a posi-
tive SLN to identify higher risk patients while potentially sparing
lower risk patients from undergoing the procedure. Several clinical
and histologic characteristics of the primary melanoma have been
examined with regard to their potential role in predicting SLN positiv-
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ity. Breslow depth has been a consistently reported
characteristic that predicts positive SLN status.2,3
Other factors that have been examined variably in-
clude patient age, anatomic location, mitotic rate,
ulceration, angiolymphatic invasion, lymphangiogen-
esis, Clark level, vertical growth phase, tumor-infiltrat-
ing lymphocytes, regression, and satellitosis.5–10
Differences in study design and data collected no
doubt explain some of the variation in factors that re-
portedly are associated significantly with positive SLN
status.
We previously reported that, in a multivariate anal-
ysis of 419 patients, Breslow depth, younger age, and
higher mitotic rate, especially in younger patients, were
associated significantly with a positive SLN and that
there was a complex relation between these factors.6 In
an attempt to validate and expand those results, we
studied a larger series of patients who underwent SLN
biopsy for cutaneous melanoma. Our objectives were to
explore the clinical and histologic characteristics of a
primary melanoma that correlate with the probability
of a positive SLN and to assess the interactions among
these factors with the goal of identifying a better
method of selecting melanoma patients for sentinel
lymph node biopsy beyond Breslow depth alone.
MATERIALS AND METHODS
Patients
This study was approved by the Institutional Review
Board at the University of Michigan. Our prospective
melanoma database was queried for patients with cuta-
neous melanoma who underwent SLN biopsy at the
University of Michigan between August 1997 and
March 2004. This included a relatively small partial
overlap of patients previously analyzed and reported
from January 1996 to August 1999 who cannot be iden-
tified completely, because their link between clinical
and research records were broken intentionally after
the publication of that study (see Results, below).6
Patients aged <16 years at the time of surgery were
excluded from the current analysis to avoid the issues
of atypical Spitz-like lesions of uncertain biologic beha-
vior and the potentially different biology of pediatric
melanomas. Patients with thin melanomas that mea-
sured <1 mm in Breslow depth also were excluded
from statistical analysis to avoid biasing the data,
because we do not offer SLN routinely to patients with
thin melanomas; our practice is to offer the procedure
for thin melanomas based on the presence of adverse
features. Finally, patients with multiple primary mela-
nomas draining to the same lymph node basin and
excised concurrently were excluded, because it is be-
lieved that these patients are have a greater likelihood
of SLN positivity. Patients were categorized by the pre-
sence or absence of metastatic melanoma in 1 SLN.
Our SLN biopsy technique and our method of SLN eva-
luation have been described previously.6,11
Statistical Analysis
Clinical variables analyzed included patient age, gen-
der, site of the primary melanoma (categorized into 4
anatomic locations: head and neck, trunk, upper ex-
tremity, or lower extremity), the number of lymph node
basins investigated during SLN biopsy, and the number
of SLNs resected. Histologic features evaluated were
Breslow depth, the number of mitoses per square milli-
meter (with 1 mm2 approximately equal to 4 or 5 high-
power [40] microscopic fields, starting in the fields
with the most mitoses), histologic subtype, and the pre-
sence or absence of the following features: ulceration,
angiolymphatic invasion, regression, neurotropism,
microsatellitosis, and periadnexal extension. All pri-
mary lesion and SLN biopsy slides were reviewed by
1 of 4 pathologists in the University of Michigan Mela-
noma Pathology Group, who generated a 14-point mel-
anoma profile for the primary lesion that included the
histologic factors described above.
The event of interest was defined as the presence of
1 positive SLN. To determine a univariate association
between any clinical or pathologic factor and the event
of interest, a logistic regression model was fit with each
factor by itself and adjusted for age (continuous term)
and gender. The parameter estimates from those mod-
els, the P value from the Wald chi-square test for the
significance of the parameter, the odds ratio (OR), and
a 95% Wald-based confidence interval (95% CI) for the
OR were reported.
To appropriately account for potential correlation
and confounding between the many clinical and patho-
logic characteristics when explaining lymph node me-
tastases, multivariate logistic regression was used. All
characteristics were modeled simultaneously in the
same logistic model, with estimates compared with the
univariate models for evidence of confounding. When
no confounding was identified, nonsignificant covari-
ates were removed from themodel by using an iterative,
stepwise variable selection procedure. The covariate
with the highest P value was removed, the model was
reestimated, and the process was repeated until only
significant (P < .05) covariates remained in the model.
Interaction between significant characteristics was
reported in our group’s earlier work.6 All 2-way interac-
tions between significant covariates were constructed
and considered in the logistic regression model. Only
significant 2-way interactions were retained, and this
model was considered our best multivariate model. All
analyses for this research were performed using SAS
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software (version 9.1; SAS Institute, Cary, NC). For mod-
eling purposes, missing data were assumed to be miss-
ing completely at random.
RESULTS
One thousand one hundred thirty-five unique mela-
noma patients who underwent SLN biopsy were identi-
fied in our database in the 6.5-year study period from
August 1997 to March 2004. One thousand one hundred
thirty patients (99.6%) had 1 SLN identified and
resected. Seventeen patients were excluded, because
they had 2 primaries draining to the same lymph node
basin that were excised concurrently. Of the remaining
1096 patients, 910 had melanoma 1 mm in Breslow
depth and were aged  16 years at the time of surgery.
These 910 patients constituted our study sample for
statistical analysis. Table 1 lists the distribution of
patient and tumor characteristics along with the per-
centage of patients with 1 positive SLN for each char-
acteristic considered. Complete information for all
characteristics considered was available in 93.4% of
patients. Patients ranged in age from 16 years to 87
years (median, 52 years). Overall, 1 positive SLNs
were identified in 243 of 910 patients (26.7%). SLN posi-
tivity rates range from 13% to 31%,2,12–18 placing our
results at the upper range of reported series. This prob-
ably was caused by several factors that limited the cur-
rent study primarily to patients with melanoma1 mm
in Breslow depth. van Akkooi et al18 reported a 29%
SLN-positivity rate for the European Organization for
Research and Treatment of Cancer melanoma Group
protocol with a mean Breslow depth of 2.76 mm. In the
current study, the mean Breslow depth was 2.57 mm.
TABLE 1









<20 y 15 53.3
20–29 y 72 37.5
30–39 y 135 31.1
40–49 y 173 32.4
50–59 y 201 23.4
60–69 y 181 16.6
70 y 133 24.8
Primary tumor site
Head and neck 176 17.6
Trunk 360 31.4
Upper extremity 180 20.0
Lower extremity 194 32.5
Histologic subtype
Acral lentiginous 33 33.3
Desmoplastic 31 12.9
Epitheloid 14 42.9




Superficial spreading 457 25.2
All others/not classified 123 24.4
Breslow depth
1.01–2 mm 490 19.4
2.01–3.99 mm 301 31.6



































No. of lymph node basins
1 742 26.7
2 168 26.8





SLN indicates sentinel lymph node.
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Univariate Analysis
Results from the univariate analyses of patient and tu-
mor characteristics with SLN positivity are summarized
in Table 2. The following characteristics were associated
significantly with a positive SLN: decreasing age (P <
.0001), increasing mitotic rate (P < .0001), increasing
Breslow depth (P < .0001), presence of angiolymphatic
invasion (P < .0001), satellitosis (P ¼ .025), ulceration
(P ¼ .005), absence of regression (P ¼ .014), and loca-
tion on the trunk (P ¼ .010) and lower extremity
(P ¼ .041) compared with tumors on the head/neck
(P ¼ .003) or upper extremity (P ¼ .024). Periadnexal
extension and neurotropism were not associated signif-
icantly with SLN positivity.
Multivariate Analysis
Results of the multivariate analyses are summarized in
Table 3. The best multivariate model included the fol-
lowing single variables: patient age (P < .0001), Breslow
depth (P ¼ .003), the presence of angiolymphatic inva-
sion (P ¼ .0001), the number of mitoses (P <.0001), and
body site location of the melanoma (P ¼ .0003). For the
purposes of the model, patients who had head and
neck melanomas were grouped with patients who had
upper extremity melanomas, because they both had an
OR < 1; and patients who had trunk and lower extrem-
ity melanomas were grouped together, because they
both had an OR > 1. In the model, the patient age at
surgery was centered at 50 years, which was chosen
because it was close to the median age (52 years) of our
patient population. The estimate for age was negative,
indicating that younger age was associated with greater
SLN positivity. Age as a single variable had a major
impact on the likelihood of SLN positivity: For a 10-year
decrease in age, the OR was 1.5; for a 20-year decrease
in age, the OR was 2.25; and, for a 30-year decrease in
age, the OR was 3.37 (as calculated from the estimate).
Thus, for example, a patient aged 20 years had >3 times
the odds of SLN positivity as a patient aged 50 years, all
other factors being equal. The presence of angiolym-
phatic invasion tripled the odds of SLN positivity (OR,
3.04). Location on the trunk and lower extremity, as
opposed to the upper extremity or head and neck,
almost doubled the odds of SLN positivity (OR, 1.92).
The estimates for the number of mitoses and for Bre-
slow depth were positive, indicating that increasing
number of mitoses and increasing Breslow depth were
associated with greater SLN positivity.
Although ulceration is used often as a determinate
for performing SLN biopsy in patients with thin mela-
nomas, it did not appear in our multivariate analysis
when mitotic rate and angiolymphatic invasion were
included. Ulceration was associated significantly with
both of these factors in our population. The patients
with ulceration had a mean mitotic rate of 4.97 com-
pared with patients without ulceration, who had a
mean mitotic rate of 2.13 (P < .0001). Of the patients
who had ulceration, 11.9% had angiolymphatic inva-
TABLE 3
Best Multivariate Model of the Relations Between Important Histologic
and Clinical Characteristics and Positive Sentinel Lymph Node Status
Characteristic P Estimate OR 95%CI
Age, linear* <.0001 0.0405 0.96 0.94–0.98
Angiolymphatic invasion .0001 1.1549 3.17 1.77–5.68
No. of mitoses/mm2, linear <.0001 0.1124 1.12 1.07–1.17
Interaction: Mitoses by age* .0097 0.00376 0.996 0.993–0.999
Breslow depth, linear .0025 0.1252 1.13 1.05–1.23
Interaction: Breslow depth by age* .0028 0.00952 1.01 1.003–1.016
Head/neck or upper extremity 0 1.00
Trunk or lower extremity .0003 0.6533 1.92 1.35–2.74
OR indicates odds ratio; 95% CI, 95% confidence interval.
* Age of the patient at surgery was centered at 50 years.
TABLE 2
Univariate Analyses of the Relations Between the Clinical and Histologic
Characteristics Considered and Positive Sentinel Lymph Node Status
Characteristic
Univariate analysis
P OR 95% CI
Men .4076 0.88 0.66–1.19
Age, linear <.0001 0.98 0.97–0.99
No. of SLNs resected, linear .0006 1.11 1.05–1.18
1 1.00
2 .2689 1.23 0.84–1.88
3 .1337 1.36 0.90–2.22
4 .0190 1.41 1.08–2.39
Angiolymphatic invasion <.0001 3.41 2.03–5.73
Regression .0137 0.55 0.34–0.88
No. of mitoses/mm2, linear <.0001 1.10 1.06–1.14
Lowmitotic rate, <1//mm2 1.00
Moderate mitotic rate, 1–5/mm2 .0001 1.97 1.42–2.82
High mitotic rate, >5/mm2 <.0001 3.20 2.11–4.85
Satellitosis .0247 2.59 1.13–5.96
Ulceration .0049 1.58 1.15–2.18
Neurotropism .3313 1.40 0.71–2.78
Periadnexal extension present .0989 2.00 0.88–4.57
Breslow depth, linear <.0001 1.22 1.13–1.31
1.01–2 mm 1.00
2.01–4 mm <.0001 1.92 1.38–2.67
4.01 mm <.0001 3.34 2.18–5.11
Head and neck location* .0027 0.53 0.35–0.80
Trunk location* .0099 1.48 1.10–1.99
Upper extremity location* .0242 0.63 0.42–0.94
Lower extremity location* .0411 1.43 1.02–2.02
OR indicates odds ratio; 95% CI, 95% confidence interval; SLN, sentinel lymph node.
* Comparing this body site with all other sites.
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sion compared with patients who did not have ulcera-
tion (4.9%; P<.0002).
Two-way Interactions
Analysis of all 2-way interactions of the variables in our
multivariate model revealed that the interaction
between patient age and the number of mitoses
(P ¼ .01) and the interaction between patient age and
Breslow depth (P ¼ .003) were statistically significant.
For the interaction between mitoses and age, the esti-
mate was negative, indicating that for a given number
of mitoses (and ignoring all other factors), the younger
patient was more likely to have a positive SLN than the
older patient. In other words, mitotic rate was a more
important predictor of SLN positivity in the younger
patient. For the interaction between Breslow depth and
age, the estimate was positive, indicating that, for a
given Breslow depth (and ignoring all other factors), the
younger patient was less likely to have a positive SLN
than an older patient. However, the magnitude of this
interaction estimate was small (0.00959) compared
with the magnitude of the estimates for Breslow depth
(0.1348) and age (0.0406), which diluted its effect in
the overall model. Still, Breslow depth was a more im-
portant predictor of SLN positivity in the older patient.
We previously reported the interactions between Bre-
slow depth and age, mitotic rate and age, and Breslow
depth and mitotic rate.6 Our results confirmed the sig-
nificant association between patient age and mitotic
rate and between age and Breslow depth, but the signif-
icant interaction between mitotic rate and Breslow
thickness previously reported was not observed in this
expanded patient series.
Body Site Location Analyses
The emergence of body site location as a potential pre-
dictor of SLN positivity, namely, that melanoma located
on the head/neck or upper extremity had a lower prob-
ability of lymph node metastases than melanoma on
the trunk or lower extremity, led to further analysis of
the possible associations between body site and the
other clinical and histologic characteristics of mela-
noma. There was no significant association between
body site and Breslow depth (P ¼ .2427), mitotic rate
(P ¼ .4741), ulceration (P ¼ .2366), angiolymphatic
invasion (P ¼ .5616), satellitosis (P ¼ .2012), or periad-
nexal extension (P ¼ .8861). However, age (P ¼ .0010),
gender (P <.0001), regression (P <.0001), neurotropism
(P ¼ .0260), and histologic subtype (P < .0001) differed
significantly by body site location. Because sex, regres-
sion, and neurotropism were not associated independ-
ently with SLN positivity, it is doubtful that they
contributed in a substantial way to the association
between SLN positivity and body site location. When
age was analyzed by body site, we observed that
patients with either head/neck or upper extremity mel-
anoma were significantly (P < .05) older than patients
with either trunk or lower extremity melanoma. In this
series, we demonstrated that increasing decreased the
likelihood of SLN positivity (Table 2); however, age also
was present in the multivariate model (Table 3), and no
significant 2-way interaction was observed; thus, the
association of body site location appears to be inde-
pendent of age.
Histologic subtype also was analyzed further for its
potential contribution to body site location as a variable
in our multivariate model. A greater proportion of
patients with head/neck melanoma had desmoplastic or
lentigo maligna subtypes, both of which had lower per-
centages metastases compared with the other subtypes,
as shown in Table 1 and as reported previously.19–21
Therefore, the analysis was repeated without the 51
patients who had either lentigo maligna or desmoplastic
melanoma. This had no effect on the end results (data
not shown), and the same factors were significant on
multivariate analysis, including anatomic location of the
primary melanoma. Hence, the significance of body site
location as a predictor of positive SLN status appears to
be independent of the histologic subtype.
Generating Predicted Probability Graphs for SLN Positivity
Using calculations directly from our multivariate
model, we generated graphs of the predicted probabil-
ities of 1 positive SLN using the variables in our
model. We analyzed the predicted probabilities in
patients with melanomas that measured from 1 mm to
2 mm in Breslow depth. This range of Breslow depth
was chosen to reflect a population of melanoma
patients with a high likelihood of having a subset of
patients who may not need SLN biopsy. Figure 1
demonstrates the predicted probabilities of a positive
SLN for melanomas between 1 mm and 2 mm in depth
on the trunk or lower extremity with angiolymphatic
invasion (Fig. 1B) and without angiolymphatic invasion
(Fig. 1A). Figure 2A,B shows the equivalent graphs for
melanomas on the upper extremity or head/neck. In all
figures, separate lines were calculated for a patient aged
35 years, 50 years, 65 years, and 80 years. Age was a lin-
ear variable in our multivariate model, but we chose
these particular ages to divide our age range roughly
into quartiles. The width of each line represents the
predicted probabilities of a positive SLN if the Breslow
depth were varied from 1 mm to 2 mm (correlating
with the lower to the upper border of the line), and the
slope of each line represents the impact of mitotic rate
on SLN positivity. In all of the figures, the width of the
lines was greatest for the patient aged 80 years, indicat-
ing that the impact of Breslow depth was greater the
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older the patient. In addition, in all of the figures, the
slope of the lines was greatest for the patient aged 35
years, indicating that the impact of mitotic rate was
greater the younger the patient. In each figure, the line
that represents the patient aged 35 years is located
above the line that represents the patient aged 50 years,
and so on; in other words, for constant body site loca-
tion, angiolymphatic invasion status, and mitotic rate,
younger patients had a much greater risk of finding a
positive SLN than older patients, regardless of the varia-
tion in Breslow depth from 1 mm to 2 mm. For all age
groups, melanoma on the head/neck or upper extrem-
ity without angiolymphatic invasion had the lowest
rates of SLN positivity.
DISCUSSION
Numerous clinical and histologic characteristics have
been reported as being predictive of SLN positivity. In
our multivariate model, using comprehensive data
from 910 patients, we observed that increasing Breslow
depth, younger patient age, higher mitotic rates, the
presence of angiolymphatic invasion, and location of
FIGURE 2. Predicted probability of 1 positive sentinel lymph node (PSLN) by
age and mitotic rate for melanoma that measured between 1 mm and 2 mm in
Breslow depth located on the head and neck or the upper extremity without
angiolymphatic invasion (A) and with angiolymphatic invasion (B). For constant
body site location, angiolymphatic invasion status, and mitotic rate, younger
patients had a much greater risk of having a positive SLN than older patients,
regardless of the variation of Breslow depth from 1 mm to 2 mm. For all age
groups, patients who had melanoma on the head/neck or upper extremity without
angiolymphatic invasion had the lowest rates of SLN positivity.
FIGURE 1. Predicted probability of 1 positive sentinel lymph node (PSLN) by
age and mitotic rate for melanoma that measured between 1 mm and 2 mm in
Breslow depth located on the trunk or lower extremity without angiolymphatic
invasion (A) and with angiolymphatic invasion (B). Separate lines were calculated
for a patient aged 35 years, 50 years, 65 years, and 80 years. The width of each
line represents the variation between 1 mm (the lower border of the line) and
2 mm (the upper border of the line). The slope of each line represents the impact
of mitotic rate. The width of the lines increases with increasing age, indicating
that the impact of Breslow depth was greater for older patients. The slope of the
line is greatest for younger patients, indicating that the impact of mitotic rate was
greater for younger patients.
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the primary melanoma on the trunk or lower extremi-
ties were significant predictors of SLN positivity.
Our current results confirm previous studies, which
showed that younger age is a predictor of SLN positiv-
ity.6,22–24 What is remarkable is just how large an effect
age had on predicting SLN positivity in our model. All
other factors being equal, a 10-year decrease in age
increased the odds of SLN positivity by 50%; a 20-year
decrease in age more than doubled the odds of SLN
positivity, and a 30-year decrease in age more than
tripled the odds of SLN positivity. Not only did age
affect the probability of SLN positivity as an independ-
ent variable, it also interacted with mitotic rate and Bre-
slow depth, validating our previous findings about
these interactions.6 Higher mitotic rate was an impor-
tant predictor of SLN positivity in younger patients, but
that importance decreased in older patients. Conver-
sely, increasing Breslow depth played a greater role in
predicting SLN positivity in older patients.
In our model, the impact of mitotic rate in predict-
ing SLN positivity was affected by patient age. In gen-
eral, higher mitotic rates were associated with SLN
positivity, but the effect was greater in younger patients.
Using Figure 1A as a visual example, we can see that the
top red line, which represents the patient aged 35 years,
has the steepest slope, indicating that, even a small
change of 1 in the mitotic rate has a significant impact
on SLN positivity. With all other variables constant, a
mitotic rate of 8 approximately doubles the likelihood
of SLN positivity compared with a mitotic rate of 0 in a
patient aged 35 years with melanoma on the trunk or
lower extremities without angiolymphatic invasion.
However, the green line, which represents the patient
aged 80 years, has a nearly horizontal line, indicating
that a mitotic rate of 0 has approximately the same like-
lihood of SLN positivity as a mitotic rate of 8.
We observed that the presence of angiolymphatic
invasion was a very significant predictor of SLN positiv-
ity. In both univariate and multivariate analyses, angio-
lymphatic invasion had a high OR of SLN positivity at
3.46 (95% CI, 2.09–5.73) and 3.04 (95% CI, 1.72–5.35),
respectively, (Tables 2, 3). The presence of angiolym-
phatic invasion tripled the odds of SLN positivity, with
all other factors in our multivariate model being con-
stant. Angiolymphatic invasion has been reported as an
adverse indicator for both SLN positivity and overall
survival in patients with melanoma.7,8,25,26
Body site location also was a significant predictor
of SLN positivity in our model. Location of the primary
melanoma on the trunk or lower extremities doubled
the odds of SLN positivity (OR, 1.92) compared with
location on the head/neck or upper extremities. The
emergence of body site location as a predictor of SLN
positivity in our study led to additional analyses to
examine associations that may contribute to the signifi-
cance of body site location, although we did not
observe any, including histologic type of melanoma. It
is noteworthy that our data on anatomic location were
divided into the trunk and lower extremities (with
greater SLN positivity) versus the head/neck and upper
extremities. This breakdown may reflect the greater
technical ease of performing SLN biopsies in the ingui-
nal basins versus cervical and axillary basins rather
than reflecting the biologic behavior of melanoma in
the different anatomic locations. Body location has
been reported quite variably and infrequently as a risk
factor for melanoma in the literature.27,28 Differences in
the data collected explain some of the discordant con-
clusions. For example, the large database analyzed to
produce the 2001 American Joint Committee on Cancer
melanoma staging system categorized location into ei-
ther head/neck/trunk or extremities.27 Other studies
have differentiated the upper arm from the lower arm
and the breast from the lower trunk.
Breslow depth is a validated, reproducible factor
that is predictive of SLN status, and it currently is the
primary criterion used to determine whether or not
SLN biopsy is considered. At National Comprehensive
Cancer Network institutions, SLN biopsy is considered
generally for melanomas that measure 1 mm and is
considered selectively for melanomas that measure
<1 mm based on the presence of other adverse factors.
To explore this criteria, we generated predicted prob-
abilities for patients with melanomas between 1 mm
and 2 mm in Breslow depth. Breslow depth played a
greater role in predicting SLN positivity in older
patients than in younger patients. This is illustrated
visually in the figures (Figs. 1A,B, 2A,B), in which the
greater width of the lines represents older patients.
What is remarkably clear is that variation in Breslow
depth from 1 mm to 2 mm had a nominal impact on
the likelihood of SLN positivity in younger patients,
with the other factors being equal. This is even more
apparent in Figure 3A,B, in which Breslow depth varies
from 2 mm to 4 mm. Mitotic rate and the presence of
angiolymphatic invasion had a greater effect on pre-
dicting SLN positivity in younger patients. Especially
for younger patients, our data support the use of patient
age, mitotic rate, angiolymphatic invasion, and ana-
tomic location, in addition to Breslow depth, when
determining whether or not to consider SLN biopsy.
The formula derived from our multivariate model,
which may be used to determine an individual patient’s
risk of harboring micrometastases in the SLN, is avail-
able online (http://www.cancer.med.umich.edu/clinic/
melclinic.htm).
If adverse factors can identify patients with mela-
nomas <1 mm for SLN biopsy, then, in theory, the ab-
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sence of those factors should select patients with mela-
nomas 1 mmwho may not require SLN biopsy. In this
analysis, the patient at lowest risk for metastatic spread
of melanoma to the SLN was the older patient with
melanoma just greater than 1 mm, without angiolym-
phatic invasion, located on the head/neck or upper
extremities. Mitotic rate had less impact on the older
patient. In the older patient with multiple medical
comorbidities, consideration of these other variables
may provide valuable information in risk assessment.
Whether these factors should be used routinely to
determine which patients undergo SLN biopsy depends
on the threshold for finding a positive SLN that justifies
the procedure. For example, if the clinician believes
that SLN biopsy is justified only if there is at least a 10%
chance of finding a positive SLN, then observation
alone would be warranted for patients aged >65 years
who have melanomas <2 mm located on the head/
neck or upper extremity without angiolymphatic inva-
sion (Fig. 2A). Identifying the most appropriate thresh-
old is a complex issue and depends on the impact of
SLN biopsy on outcome, which still is being explored.
Beyond the implications of these data on clinical
practice, our findings raise an interesting biologic ques-
tion. Although younger patients have a significantly
greater risk of positive SLN status, and a positive SLN
clearly is associated with a poor outcome, older patients
typically have a worse prognosis. This suggests a differ-
ence in the biology of the disease in younger patients
compared with older patients. Whether this represents
differences in the primary melanoma (such as a greater
proclivity for hematogenous spread in older patients) or
the patient’s response (such as a diminished capability
of the immune system to eradicate systemic disease in
older patients) is unclear and begs further exploration.
In conclusion, younger age, increasing mitotic rate
(especially in younger patients), increasing Breslow
depth (especially in older patients), the presence of
angiolymphatic invasion, and location of the primary
tumor on the trunk or lower extremities are associated
with higher likelihood of positive SLN status. The cur-
rent results support the use of factors beyond Breslow
depth to determine the risk of SLN positivity in patients
with cutaneous melanoma and provide a better model
for determining which patients should undergo SLN bi-
opsy and which patients may undergo wide local exci-
sion alone. In addition, further research into the
variations of behavior of melanoma in younger and
older populations warrants further investigation.
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